CURATIS N AG (CURN.SW) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH1330780979
CURATIS N AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 6.90 m CHF | 10.80 m CHF |
| Gross profit | 1.59 m CHF | 2.84 m CHF |
| Operating income | -3.25 m CHF | -1.55 m CHF |
| EBIT | -4.59 m CHF | -1.51 m CHF |
| Net income | -4.35 m CHF | -1.42 m CHF |
| Diluted EPS – continuing operations | -1.49 CHF | -0.28 CHF |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.
More stocks
- Southern Silver Exploration Corp. (SSV.V)
- T3 Entertainment Inc. (204610.KQ)
- Lin Horn Technology Co Ltd (5464.TWO)
- DeviceENG.CO.Ltd (187870.KQ)
- Zomedica Corp. (ZOMDF)
- Anterogen.Co.Ltd (065660.KQ)
- Perspective Therapeutics, Inc. (CATX)
- SPSoft Inc. (443670.KQ)
- Shinhung (004080.KS)
- AEWIN Technologies Co.Ltd. (3564.TWO)
- Patria Bank SA (PBK.RO)
- Pharmosa Biopharm Inc. (6875.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.